<DOC>
	<DOCNO>NCT01334034</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate safety , tolerability , pharmacokinetics ( exposure trial drug body ) , pharmacodynamics ( effect investigate drug body ) NNC 0123-0000-0338 tablet healthy subject .</brief_summary>
	<brief_title>Safety NNC 0123-0000-0338 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Male subject Body mass index ( BMI ) 18 28 kg/m^2 ( inclusive ) Known suspect hypersensitivity trial product relate product Presence clinically significant acute gastrointestinal symptom ( e.g . nausea , vomit , heartburn diarrhoea ) within 2 week prior dose , judge trial physician Presence medical condition may confound result trial pose unacceptable risk subject administer trial product , judge trial physician</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>